Tanja S. Zabka

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index2.1kcitations87works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(21), Bladder and Urothelial Cancer Treatments(14), Amino Acid Enzymes and Metabolism(12), Veterinary Oncology Research(10), Marine Toxins and Detection Methods(7)

Publications87 total

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development
Clinical Pharmacology & Therapeutics·2025Open Access
P06-22 Assay validation and quantification of novel urinary kidney safety biomarker candidates for the detection of glomerular injury in clinical specimens
Toxicology Letters·2025
Emerging neurology safety biomarkers for advanced modality therapeutic-associated neurotoxicity in nonhuman primates
Journal of Pharmacological and Toxicological Methods·2025
Chlamydial infections in free-ranging raptors presenting to a university veterinary medical teaching hospital (1993–2022)
American Journal of Veterinary Research·2025· 1 citedOpen Access
P06-10 NGS-based discovery of circulating microRNA biomarkers of drug-induced pancreatic injury (DIPI)
Toxicology Letters·2024
Role of Na<sub>V</sub>1.7 in postganglionic sympathetic nerve function in human and guinea‐pig arteries
The Journal of Physiology·2024· 10 citedOpen Access
Effect of Na<sub>V</sub>1.7 blockers on post-ganglionic sympathetic nerve function
Physiology·2024
Nonclinical pharmacokinetics, pharmacodynamics and safety assessment of a FLT3L-Fc molecule for cancer immunotherapy
Toxicology and Applied Pharmacology·2024· 4 cited
Supplementary Table S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Data from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Supplementary Table S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Figure S4 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Supplementary Table S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Figure S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Figure S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Figure S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Figure S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Supplementary Table S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Figure S5 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
Figure S5 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, &lt;i&gt;BRAF&lt;/i&gt;-mutated Urothelial Carcinoma
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Frances M. D. Gulland(8), Dinah Misner(5), Deepak Sampath(4), Peter S. Dragovich(4), Martin Haulena(4), Tracey Goldstein(4), Hirdesh Uppal(4), Thomas O’Brien(3), Gregg W. Langlois(3), Jatinder Singh(3), Tori Lin(3), Bobbi McCray(3), Nghi La(3), Trung Van Nguyen(3), Silvia Guionaud(3), Marshall S. Scicchitano(3), James L. Weaver(3), Mudher Albassam(3), Thomas P. Singer(3), Kyle L. Kolaja(3)